Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ZBIO

Zenas Biopharma Inc

Dec 13 • 04:00PM ET

8.92

Dollar change -0.33
Percentage change -3.57	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	76.39%	Shs Outstand	41.78M	Perf Week	-17.79%
Market Cap	372.78M	Forward P/E	-	EPS next Y	-	Insider Trans	18.13%	Shs Float	11.31M	Perf Month	-53.30%
Income	-	PEG	-	EPS next Q	-1.01	Inst Own	25.81%	Short Float	13.00%	Perf Quarter	-50.36%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	6.20	Perf Half Y	-
Book/sh	8.60	P/B	1.04	EPS next Y	-	ROA	-	Short Interest	1.47M	Perf Year	-
Cash/sh	9.26	P/C	0.96	EPS next 5Y	-	ROE	-	52W Range	8.89 - 26.25	Perf YTD	-50.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-66.02%	Beta	-
Dividend TTM	-	Quick Ratio	8.95	Sales past 5Y	0.00%	Gross Margin	-	52W Low	0.39%	ATR (14)	1.41
Dividend Ex-Date	Dec 24, 2019	Current Ratio	8.95	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	26.65	Volatility	8.38% 13.35%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	35.20
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-21.88%	Payout	-	Rel Volume	1.12	Prev Close	9.25
Sales Surprise	-	EPS Surprise	-427.92%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	237.19K	Price	8.92
SMA20	-21.60%	SMA50	-46.93%	SMA200	-47.79%	Trades		Volume	265,223	Change	-3.57%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
04:15PM	Loading…
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	Dec 04 '24	Buy	9.98	45,000	449,100	241,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 03 '24	Buy	10.76	25,000	269,000	196,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 18 '24	Buy	15.00	7,500	112,500	168,655	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 19 '24	Buy	14.57	2,500	36,425	171,155	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 18 '24	Buy	17.91	10,000	179,100	1,662,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 20 '24	Buy	18.45	5,000	92,270	1,672,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 19 '24	Buy	17.89	5,000	89,450	1,667,039	Sep 20 06:34 PM
Enavate Sciences GP, LLC	10% Owner	Sep 16 '24	Buy	17.00	882,353	15,000,001	3,761,359	Sep 18 04:15 PM
Lu Hongbo	Director	Sep 13 '24	Buy	17.00	58,823	999,991	58,823	Sep 17 07:52 PM
ENRIGHT PATRICK G	Director	Sep 16 '24	Buy	17.00	440,000	7,480,000	774,530	Sep 16 08:57 PM
Nunn Jason Raleigh	Director	Sep 16 '24	Buy	17.00	882,352	14,999,984	1,946,564	Sep 16 08:54 PM
Fairmount Funds Management LLC	Director	Sep 16 '24	Buy	17.00	300,000	5,100,000	1,604,891	Sep 16 08:54 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 16 '24	Buy	17.00	2,235,294	37,999,998	1,946,564	Sep 16 08:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZBIO

Zenas Biopharma Inc

Upgrade your FINVIZ experience